Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
When patients progress on PI3K/AKT inhibitors like CAPF assertive, resistance is not primarily driven by new mutations within the PI3K pathway. In one trial, only 6% of patients developed such alterations. This suggests resistance mechanisms involve the activation of other signaling pathways, a key consideration for developing future combination therapies.
Related Insights
The next evolution in this drug class involves inhibitors that only target mutated PI3K. This specificity aims to avoid effects on wild-type PI3K, which is involved in insulin signaling. The goal is to dramatically reduce severe side effects like hyperglycemia, which could allow for higher, more effective drug doses.
When patients present with both ESR1 and PI3K mutations, treatment selection isn't based on a definitive molecular test. Instead, oncologists make a clinical judgment, inferring the dominant resistance pathway from factors like the duration of prior therapy to guide their choice of targeted agent.
Next-generation mutant-specific PI3K inhibitors could lead to complex biomarker requirements. A future drug label might require a PIK3CA mutation for eligibility but simultaneously exclude patients who also have downstream PTEN or AKT alterations, which can confer resistance.
While MEN1 mutations cause resistance, they don't explain all treatment failures, especially with agents like Ziftomenib. Other mechanisms, including activation of RTK pathways (RAS, FLT3) and epigenetic bypass, are key drivers of acquired resistance.
Despite alpelisib directly targeting the upstream PIK3CA mutation, clinicians have almost completely shifted to the downstream AKT inhibitor capivasertib in the second-line setting. This practical decision is driven by capivasertib's significantly better side effect profile and ease of management.
Retrospective analysis of the BOLERO-2 trial revealed that the mTOR inhibitor everolimus benefits patients irrespective of their PI3K mutation status. This challenges the assumption that pathway-targeted therapies are only effective when a specific mutation is present, suggesting broader mechanisms of action.
Data from older studies suggests that PI3K inhibitors and mTOR inhibitors (like everolimus) have distinct mechanisms and may not be cross-resistant. This allows clinicians to confidently sequence these agents, for example using everolimus after progression on a PI3K or AKT inhibitor, providing more lines of targeted therapy.
The IV drug gedatolisib, which inhibits the entire PI3K/AKT/mTOR pathway, is highly effective even in patients *without* PIK3CA mutations. This suggests pathway activation is not solely mutation-driven and creates a new option for a biomarker-negative patient group.
The Victoria 1 study showed that adding a CDK4/6 inhibitor (triplet therapy) improved outcomes only in patients with PIK3CA wild-type tumors. In PIK3CA-mutant tumors, the doublet therapy was equally effective. This surprising finding highlights that distinct resistance mechanisms are at play and that mutation status is critical for selecting optimal combination regimens.
Using capivasertib in the hormone-sensitive setting is preferred because the cancer is more likely dependent on the AKT pathway for growth. In later, castration-resistant stages, additional genetic alterations can emerge, creating redundant growth signals and potentially diminishing the inhibitor's efficacy.
